Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with Cystic Fibrosis-Reference-Cited by-同舟云学术

Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with Cystic Fibrosis

Published:2020-07 Issue:4 Volume:19 Page:562-568
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Boon M.^ORCID,Calvo-Lerma J.,Claes I.,Havermans T.,Asseiceira I.,Bulfamante A.,Garriga M.,Masip E.,van Schijndel B.A.M.,Fornes V.,Barreto C.,Colombo C.,Crespo P.,Vicente S.,Janssens H.,Hulst J.,Witters P.,Nobili R.,Pereira L.,Ruperto M.,Van der Wiel E.,Mainz J.G.,De Boeck K.,Ribes-Koninckx C.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference25 articles.

1. Nutritional care in children with cystic fibrosis: are our patients becoming better?;Gaskin;Eur J Clin Nutr,2013

2. Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency;Layer;World J Gastroenterol,2019

3. European cystic fibrosis society standards of care: best practice guidelines;Smyth;J Cyst Fibros,2014

4. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis;Turck;Clin Nutr,2016

5. Pancreatic insufficiency in cystic fibrosis;Singh;J Cyst Fibros,2017

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exocrine pancreatic insufficiency: more compromise than precision;Hepatobiliary Surgery and Nutrition;2024-06

2. Scoring Abdominal Symptoms in People with Cystic Fibrosis;Journal of Clinical Medicine;2024-03-13

3. Long-term evaluation of faecal calprotectin levels in a European cohort of children with cystic fibrosis;Archives of Disease in Childhood;2023-12-18

4. Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire;Frontiers in Pharmacology;2023-10-25

5. Dynamics of abdominal symptoms during the start of a new therapy with Elexacaftor/Tezacaftor/Ivacaftor using the novel CFAbd-day2day questionnaire;2023-08-02